Tumor DNA from tumor <i>in situ</i> fluid was used to track evolution of glioma under first-line treatment.

ABSTRACT:

Introduction

Few studies have tracked the genetic evolution of glioma recurrence in patients after surgery. We conducted a systematic review through an innovative sampling method, which made post-operative follow-up possible. Tumor DNA from Tumor in situ fluid (TISF) was used to trace the genetic landscape of gliomas at different stages of recurrence and evolution.

Methods

We recruited 60 patients with WHOII-III gliomas diagnosed more than 6 years ago. We performed whole exome sequencing (WES) of primary tumor tissues and paired TISF to identify somatic mutations by personalized, tumor-informative TISF-DNA testing. TISF and recurrent tumor tissues were collected at simultaneous and 2-3 month routine visits. Patients were followed up for clinical recurrence.

Results

In

SUBMITTER: Yu J 

PROVIDER: S-EPMC12571563 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature